


RARE BONE DISEASE HIGHLIGHTS

FROM THE **ASBMR 2022** ANNUAL MEETING: PATIENT ADVOCATE PERSPECTIVE

PATIENT ADVOCACY BRIDGES (PRE-)CLINICAL AND PATIENT COMMUNITIES



INSIGHTS ON OI

- The IMPACT survey in OI explores the clinical, quality of life and economic challenges faced by OI patients around the world
- More than 2000 survey participants from 66 countries
- Self-perception of pain and self-identification of disease severity may have significant impact on therapy decisions



A CHANGING PARADIGM

Patient experts' collaboration in research can **reduce development timelines** for novel therapies

A RESPONSIBILITY

Of patient representatives to keep patient communities **informed about new and ongoing research efforts**

A NOVEL PLATFORM

Expanding from the paradigm of pharmacological therapy of rare bone disease, ongoing research on **nanoparticle-mediated siRNA delivery** to mutation sites may represent a new approach to future therapies

OI: osteogenesis imperfecta
siRNA: small interfering ribonucleic acid

This educational content was developed in partnership between COR2ED and the American Society for Bone and Mineral Research, supported by an independent medical education grant from the Rare Bone Disease Consortium, represented by Alexion, AstraZeneca Rare Disease, by Ipsen and by Kyowa Kirin, who had no input into selection of topics or speakers

September 2022

Access the ASBMR 2022 Rare Bone Disease Highlights podcast series

